Accera commences clinical efficacy trial of AC-1204 for mild-to-moderate Alzheimers disease Accera.

These three hospitals accounted for much of the excess risk in this mixed group, including 72 percent of the baseline coagulase-bad staphylococcal bloodstream infections . The baseline risk per affected individual in all other hospitals in group 3 was similar to the baseline risks in all hospitals in groups 1 and 2 . During the intervention period, the chance declined in the three hospitals and in all other hospitals implementing universal decolonization , in comparison with the baseline risks and in comparison with the intervention risk for organizations 1 and 2 .